Vericel Corp. (NASDAQ:VCEL) shares were down 4.1% during mid-day trading on Thursday . The stock traded as low as $2.12 and last traded at $2.12, with a volume of 70,507 shares. The stock had previously closed at $2.21.

Several research analysts have recently issued reports on VCEL shares. Needham & Company LLC restated a “buy” rating and issued a $12.00 price target on shares of Vericel Corp. in a research report on Tuesday, April 5th. Bank of America Corp. lowered Vericel Corp. from a “buy” rating to a “neutral” rating in a research report on Tuesday, April 5th.

The firm has a 50-day moving average of $2.41 and a 200-day moving average of $2.80. The firm’s market cap is $47.32 million.

Vericel Corp. (NASDAQ:VCEL) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.17. The business earned $14.10 million during the quarter, compared to analysts’ expectations of $11.60 million. Equities research analysts predict that Vericel Corp. will post ($0.79) EPS for the current year.

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.